留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Banff移植肾病理电子显微镜诊断标准及其进展

黄亚冰 郭晖 官阳 钟伟雄

黄亚冰, 郭晖, 官阳, 等. Banff移植肾病理电子显微镜诊断标准及其进展[J]. 器官移植, 2021, 12(4): 391-396. doi: 10.3969/j.issn.1674-7445.2021.04.004
引用本文: 黄亚冰, 郭晖, 官阳, 等. Banff移植肾病理电子显微镜诊断标准及其进展[J]. 器官移植, 2021, 12(4): 391-396. doi: 10.3969/j.issn.1674-7445.2021.04.004
Huang Yabing, Guo Hui, Guan Yang, et al. Progress on electron microscopy diagnosis on Banff classification for renal allograft pathology[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 391-396. doi: 10.3969/j.issn.1674-7445.2021.04.004
Citation: Huang Yabing, Guo Hui, Guan Yang, et al. Progress on electron microscopy diagnosis on Banff classification for renal allograft pathology[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 391-396. doi: 10.3969/j.issn.1674-7445.2021.04.004

Banff移植肾病理电子显微镜诊断标准及其进展

doi: 10.3969/j.issn.1674-7445.2021.04.004
基金项目: 

国家自然科学基金重大研究计划培育项目 91130034

武汉大学医学部教学研究项目 2020025

详细信息
    作者简介:

    黄亚冰,女,1978年生,主治医师,Email: ybhuang@whu.edu.cn

    通讯作者:

    官阳,男,1964年生,博士,主任医师,研究方向为超微病理学,Email:guanyang@foxmail.com

    钟伟雄,男,1957年生,博士,副教授,研究方向为肾病及肾移植病理,Email:wzhong3@wisc.edu

  • 中图分类号: R617, R36

Progress on electron microscopy diagnosis on Banff classification for renal allograft pathology

More Information
  • 摘要: 随着临床器官移植的发展,移植病理学也在不断发展和提高。其中,Banff移植病理学会议的召开及Banff移植病理学诊断标准(Banff标准)的建立是国际移植病理学发展的重要里程碑。自此之后,各类移植器官病理学诊断的Banff标准得以不断更新和完善。电子显微镜(电镜)的超微病理学观察在移植肾早期抗体介导的排斥反应、移植肾复发性疾病和新发性疾病的早期诊断中具有不可替代的作用,早期发现和早期合理治疗有助于保障移植肾的长期存活,减少移植肾失功。本文介绍了电子显微镜及其超微病理诊断的基本定义、Banff移植肾病理中有关电镜诊断标准的研究历程及主要进展,总结了在移植肾活检电镜诊断中的典型病变、标准术语及诊断标准,旨在为临床器官移植及基础器官移植研究提供参考。

     

  • 图  1  移植肾特征性病变的电镜表现

    注:A图为内皮细胞增大的电镜表现(×3 000);B图为内皮下间隙增宽的电镜表现(×12 000);C图为肾小球内皮下新生致密基底膜的电镜表现(×4 000);D图为PTCML的电镜表现(×3 000)。

    Figure  1.  Electron microscopic findings of characteristic lesions of renal allograft

  • [1] 郭晖, 陈刚. Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用[J]. 器官移植, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.

    GUO H, CHEN G. The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation[J]. Organ Transplant, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.
    [2] 郭晖. 移植肾抗体介导的排斥反应的病理学[J]. 器官移植, 2021, 12(3): 262-271. DOI: 10.3969/j.issn.1674-7445. 2021.03.003.

    GUO H. Pathology of antibody-mediated rejection in renal allograft[J]. Organ Transplant, 2021, 12(3): 262-271. DOI: 10.3969/j.issn.1674-7445.2021.03.003.
    [3] YOKOYAMA H, OKADA S, YAMADA Y, et al. Low-vacuum scanning electron microscopy may allow early diagnosis of human renal transplant antibody-mediated rejection[J]. Biomed Res, 2020, 41(2): 81-90. DOI: 10. 2220/biomedres.41.81.
    [4] ONISHI H, OGUCHI H, SHINODA K, et al. Pathological analysis of early transplant glomerulopathy in renal allografts using low-vacuum scanning electron microscopy[J]. Nephron, 2020, 144 (Suppl 1): 71-78. DOI: 10.1159/000512136.
    [5] MOROZUMI K, TAKEDA A, OTSUKA Y, et al. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation[J]. Nephrology (Carlton), 2016, 21 (Suppl 1): 4-8. DOI: 10.1111/nep.12777.
    [6] 武忠弼. 超微病理诊断学[M]. 上海: 上海科学技术出版社, 2003.
    [7] 史景泉, 陈意生, 卞修武. 超微病理学[M]. 北京: 化学工业出版社, 2005.
    [8] HAAS M. Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts[J]. Curr Opin Nephrol Hypertens, 2018, 27(3): 137-143. DOI: 10.1097/MNH.0000000000000398.
    [9] CHAPMAN JR, WAVAMUNNO M, O'CONNELL PJ, et al. Unravelling the connections between donor specific antibodies and renal allograft pathology[J]. Clin Transpl, 2013: 361-365. http://europepmc.org/abstract/med/25095530
    [10] HAAS M. Pathology of C4d-negative antibody-mediated rejection in renal allografts[J]. Curr Opin Organ Transplant, 2013, 18(3): 319-326. DOI: 10.1097/MOT.0b013e32835d4daf.
    [11] PAPADIMITRIOU JC, DRACHENBERG CB, RAMOS E, et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies[J]. Transplantation, 2013, 95(1): 128-136. DOI: 10.1097/TP.0b013e3182777f28.
    [12] SNIJDERS MLH, VAROL H, VAN DER ZWAN M, et al. Molecular analysis of renal allograft biopsies: where do we stand and where are we going?[J]. Transplantation, 2020, 104(12): 2478-2486. DOI: 10.1097/TP.0000000000003220.
    [13] KIM MY, BRENNAN DC. Therapies for chronic allograft rejection[J]. Front Pharmacol, 2021, 12: 651222. DOI: 10.3389/fphar.2021.651222.
    [14] SOLAR-CAFAGGI D, MARINO L, URIBE-URIBE N, et al. Antibody-mediated rejection in the Banff classifications of 2007 and 2017: a comparison of renal graft loss prediction capability[J]. Transpl Immunol, 2018, 51: 40-44. DOI: 10.1016/j.trim.2018.08.008.
    [15] HAAS M. The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations[J]. Am J Transplant, 2016, 16(5): 1352-1357. DOI: 10.1111/ajt.13661.
    [16] MONGA G, MAZZUCCO G, NOVARA R, et al. Intertubular capillary changes in kidney allografts: an ultrastructural study in patients with transplant glomerulopathy[J]. Ultrastruct Pathol, 1990, 14(3): 201-209. DOI: 10.3109/01913129009076124.
    [17] MONGA G, MAZZUCCO G, MESSINA M, et al. Intertubular capillary changes in kidney allografts: a morphologic investigation on 61 renal specimens[J]. Mod Pathol, 1992, 5(2): 125-130.
    [18] FILIPPONE EJ, MCCUE PA, FARBER JL. Transplant glomerulopathy[J]. Mod Pathol, 2018, 31(2): 235-252. DOI: 10.1038/modpathol.2017.123.
    [19] VAZQUEZ MARTUL E. The pathology of renal transplants[J]. Rev Esp Patol, 2018, 51(2): 110-123. DOI: 10.1016/j.patol.2017.10.001.
    [20] LOUPY A, HAAS M, SOLEZ K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41. DOI: 10.1111/ajt.14107.
    [21] LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331. DOI: 10.1111/ajt.15898.
    [22] HAAS M, LOUPY A, LEFAUCHEUR C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials[J]. Am J Transplant, 2018, 18(2): 293-307. DOI: 10.1111/ajt.14625.
    [23] DE SERRES SA, NOËL R, CÔTÉ I, et al. 2013 Banff criteria for chronic active antibody-mediated rejection: assessment in a real-life setting[J]. Am J Transplant, 2016, 16(5): 1516-1525. DOI: 10.1111/ajt.13624.
    [24] SENEV A, COEMANS M, LERUT E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome[J]. Am J Transplant, 2019, 19(3): 763-780. DOI: 10.1111/ajt.15074.
    [25] SABLIK KA, CLAHSEN-VAN GRONINGEN MC, LOOMAN CWN, et al. Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study[J]. Transpl Int, 2018, 31(8): 900-908. DOI: 10.1111/tri.13154.
    [26] PARAJULI S, REDFIELD RR, GARG N, et al. Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation[J]. Transplantation, 2019, 103(7): 1468-1476. DOI: 10.1097/TP.0000000000002487.
    [27] WANG J, LI X, WU X, et al. Gut microbiota alterations associated with antibody-mediated rejection after kidney transplantation[J]. Appl Microbiol Biotechnol, 2021, 105(6): 2473-2484. DOI: 10.1007/s00253-020-11069-x.
    [28] CLOTET-FREIXAS S, MCEVOY CM, BATRUCH I, et al. Extracellular matrix injury of kidney allografts in antibody-mediated rejection: a proteomics study[J]. J Am Soc Nephrol, 2020, 31(11): 2705-2724. DOI: 10.1681/ASN.2020030286.
  • 加载中
图(2)
计量
  • 文章访问数:  178
  • HTML全文浏览量:  63
  • PDF下载量:  31
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-07
  • 网络出版日期:  2021-07-13
  • 刊出日期:  2021-07-15

目录

    /

    返回文章
    返回